Style Editor Docs
     
  • RadioGel™
    • Precision Radionuclide Therapy (PRnT)
    • US FDA IDE Pre-Submission
      • US FDA IDE Updates
    • Human Clinical Trials
  • IsoPet®
    • Regional Clinics
      • IsoPet® Therapy Dog • Cat Application
      • IsoPet® Therapy Equine Application
    • IsoPet® Therapy Pets
    • Veterinarians
    • Animal Studies
      • Canine Studies
      • Feline Studies
    • Our IsoPet® Mission
  • About Us
    • Management & Consultants
    • Advisory Boards
    • Contact - RadioGel™ | IsoPet®
  • Blog
  • Investors
    • Press Releases
    • Board of Directors
    • SEC Filings
    • Contact - Investor Relations
   Contact Us
  • RadioGel™
    • Precision Radionuclide Therapy (PRnT)
    • US FDA IDE Pre-Submission
      • US FDA IDE Updates
    • Human Clinical Trials
  • IsoPet®
    • Regional Clinics
      • IsoPet® Therapy Dog • Cat Application
      • IsoPet® Therapy Equine Application
    • IsoPet® Therapy Pets
    • Veterinarians
    • Animal Studies
      • Canine Studies
      • Feline Studies
    • Our IsoPet® Mission
  • About Us
    • Management & Consultants
    • Advisory Boards
    • Contact - RadioGel™ | IsoPet®
  • Blog
  • Investors
    • Press Releases
    • Board of Directors
    • SEC Filings
    • Contact - Investor Relations
  1. IsoPet®
  2. Regional Clinics
  3. IsoPet® Therapy Equine Application

IsoPET® Therapy | Equine patient expression of interest

IsoPet® is now commercially available as part of a company-sponsored program to gain experience on the use of the product and to share the results of this therapy with the veterinary community. Interested animal owners will have this completed form sent to Vivos, Inc CEO | President Dr. Mike Korenko.  

University of Missouri Department of Veterinary medicine will review the information and provide their recommendation regarding applicability of IsoPet® therapy.

Important information regarding IsoPet®:


IsoPet® is designed to deliver a high dose of therapeutic radiation at the point of administration with no significant radiation extending beyond the treatment zone. The hydrogel immobilizes the yttrium-90 phosphate particles to prevent any contamination in urine or feces. With a 2.7-day half-life the majority of the dose is administered over the first ten days and then the radioactivity quickly decays.

IsoPet® is most appropriate for treating localized cancers, especially solid tumors with well-defined boundaries or margins. IsoPet® is particularly attractive for treating tumors that would be difficult to remove surgically (non-resectable) but could be reached with a needle for injecting the product.

IsoPet is not effective against distributed cancers, such as lymphomas, or advanced metastatic disease where the cancer has spread significantly beyond the tumor site. IsoPet can only be expected to effectively treat the primary tumor.

Please enter the code:

Note: Please fill out the fields marked with an asterisk.

General Understanding:

You will be participating in a developmental therapy. The therapy has demonstrated limited, but positive results. The data from the tests will be made available to Vivos Inc. and other clinics and could be included in published paper or conferences. Since it is developmental the pet owner recognizes there are risks.

 

IsoPET® therapy price is competitive with the cost of external beam radiation therapy.

Vivos, Inc.

Precision Radionuclide Therapy (PRnT)

OTCQB: RDGL

contact: info@radiogel.com


Home Page Cover Image: 

 

Veterinarian Dr. Michelle Myer from Vista Veterinarian Hospital in Kennewick, WA.

 

Seen here administering IsoPet® therapy to a feline suffering from a sarcoma.

RadioGel™ is a hydrogel liquid containing tiny yttrium-90 (90Y)  phosphate particles that may be administered directly into a tumor. The hydrogel is an yttrium-90 carrier at room temperature that gels within the tumor interstitial spaces after injection to keep the radiation sources safely in place. The short-range beta radiation from yttrium-90 localizes the dose within the treatment area so that normal organs and tissues are not adversely affected.

IsoPet® Therapy Application(s)


Precision Radionuclide Therapy (PRnT)


Vivos Inc.
 - (OTCQB: RDGL) Investor Relations 

Contact

 

Main colors
   bg-primary
   bg-primary-light
   bg-primary-dark
   bg-secondary
   bg-secondary-dark
Template sections
   body
   top-header
   header
   content
Footer Styles
   background
   text color
   link color
   horizontal line
Buttons
   style 1
   style 2
   style 3
Other elements
  social icons
  navigation color
  subnav background
Mobile navigation
   background color
   navigation color
Template configurations
has-right-nav g-font
navigation styles
size-15 weight-400 snip-nav
content styles
form-white
footer styles
o-form color-white
Typography
Heading H1
weight-600
Heading H2
weight-600
Heading H3
weight-600
Buttons
weight-600 is-uppercase
Animations

Note:
All changes made here will be applied to your entire website.
is-switcher admin-only

RadioGel™ Logo

Precision Radionuclide Therapy (PRnT)

draggable-logo

About | Privacy Policy | Cookie Policy | Sitemap
© 2022 Vivos Inc. | RadioGel™ is a registered trademark | IsoPet® is a registered trademark
Log out | Edit
  • Regional Clinics
    • IsoPet® Therapy Dog • Cat Application
    • IsoPet® Therapy Equine Application
  • IsoPet® Therapy Pets
  • Veterinarians
  • Animal Studies
  • Our IsoPet® Mission
  • Scroll to top